KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Treasury Shares (2018 - 2025)

Aquestive Therapeutics has reported Treasury Shares over the past 8 years, most recently at $1.7 million for Q4 2025.

  • Quarterly results put Treasury Shares at $1.7 million for Q4 2025, down 33.79% from a year ago — trailing twelve months through Dec 2025 was $1.7 million (down 33.79% YoY), and the annual figure for FY2025 was $1.7 million, down 33.79%.
  • Treasury Shares for Q4 2025 was $1.7 million at Aquestive Therapeutics, down from $2.9 million in the prior quarter.
  • Over the last five years, Treasury Shares for AQST hit a ceiling of $3.3 million in Q2 2025 and a floor of $8000.0 in Q2 2021.
  • Median Treasury Shares over the past 5 years was $1.8 million (2023), compared with a mean of $1.5 million.
  • Biggest five-year swings in Treasury Shares: crashed 68.18% in 2021 and later surged 2025.0% in 2022.
  • Aquestive Therapeutics' Treasury Shares stood at $8000.0 in 2021, then soared by 1925.0% to $162000.0 in 2022, then soared by 1102.47% to $1.9 million in 2023, then soared by 33.98% to $2.6 million in 2024, then crashed by 33.79% to $1.7 million in 2025.
  • The last three reported values for Treasury Shares were $1.7 million (Q4 2025), $2.9 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.